Role of levonorgestrel releasing intra-uterine system in the treatment of menorrhagia due to dysfunctional uterine bleeding and fibroid uterus

Authors

  • Reena Gupta Department of Obstetrics and Gynaecology, VMMC and Safdarjung Hospital, New Delhi-110029, India
  • Rupali Dewan Department of Obstetrics and Gynaecology, VMMC and Safdarjung Hospital, New Delhi-110029, India
  • Pratima Mittal Department of Obstetrics and Gynaecology, VMMC and Safdarjung Hospital, New Delhi-110029, India
  • Jyotsna Suri Department of Obstetrics and Gynaecology, VMMC and Safdarjung Hospital, New Delhi-110029, India
  • Abhinav Dewan Department of Obstetrics and Gynaecology, VMMC and Safdarjung Hospital, New Delhi-110029, India
  • Rekha Bharti Department of Obstetrics and Gynaecology, VMMC and Safdarjung Hospital, New Delhi-110029, India

Keywords:

Levonorgestrel releasing intrauterine device, Menorrhagia, Fibroid, Dysfunctional uterine bleeding

Abstract

Background: This study was carried out to assess the clinical effectiveness of levonorgestrel releasing intrauterine device (LNG-IUS) in the treatment of menorrhagia due to either Dysfunctional Uterine Bleeding (DUB) or fibroid in Indian patients, and to assess patient satisfaction with this treatment modality.  

Methods: Sixty women with menorrhagia, 30 due to fibroid and 30 due to DUB, meeting inclusion criteria, received LNG-IUS and were prospectively followed up for 9 months with periodic clinical assessments and transvaginal ultrasounds. Patient satisfaction was assessed on a five-point scale.

Results: One patient in DUB group was lost to follow-up. In DUB patients, the treatment failure rate was only 3.4% (1 out of 29 patients). The median PBAC score reduced by 95% at 9 months. Fibroid patients also had an equally impressive 97.7% reduction of PBAC score at 9 months, although the failure rate was higher (23.3%; 7 out of 30). Majority of patients were either ‘very satisfied’ or ‘satisfied’ with the treatment, although this percentage was more in DUB (82.8%) than in the fibroid group (66.7%). Haemoglobin and serum ferritin levels significantly increased in both groups. No major side effect was noted.

Conclusions: LNG-IUS is an excellent treatment modality for patients of DUB, with good patient satisfaction. It is also a useful treatment option in non-submucosal small fibroids for the symptoms of menorrhagia, can reduce uterine volume and can help avoid hysterectomy, but there is no effect on fibroid volume. Majority of patients are satisfied, although satisfaction rates are less than in DUB patients.

References

Hallberg L, Högdahl AM, Nilsson L, Rybo G. Menstrual blood loss: a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynaecol Scand. 1966;45(3):320-51.

Shaw RW. Assessment of medical treatments for menorrhagia. Br J Obstet Gynaecol. 1994 Jul;101(Suppl 11):15-8.

Stewart EA. Uterine fibroids. Lancet. 2001 Jan;357(9252):293-8.

Stirrat GM. Choice of treatment for menorrhagia. Lancet. 1999 Jun;353(9171):2175-6.

Vuorma S, Teperi J, Hurskainen R, Keskimäki I, Kujansuu E. Hysterectomy trends in Finland in 1987-1995: a register based analysis. Acta Obstet Gynaecol Scand. 1998 Aug;77(7):770-6.

Hubacher D, Grimes DA. Non-contraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynaecol Surv. 2002 Feb;57(2):120-8.

Hurskainen R, Teperi J, Rissanen P, Aalto A-M, Grenman S, Kivelä A, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA. 2004 Mar;291(12):1456-63.

Rauramo I, Elo I, Istre O. Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection. Obstet Gynaecol. 2004 Dec;104(6):1314-21.

Machado RB, de Souza IM, Beltrame A, Bernardes CR, Morimoto MS, Santana N. The levonorgestrel-releasing intrauterine system: its effect on the number of hysterectomies performed in perimenopausal women with uterine fibroids. Gynecol Endocrinol. 2013 May;29(5):492-5.

Chattopdhyay B, Nigam A, Goswami S, Chakravarty PS. Clinical outcome of levonorgestrel intra-uterine system in idiopathic menorrhagia. Eur Rev Med Pharmacol Sci. 2011 Jul;15(7):764-8.

Luukkainen T, Lähteenmäki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med. 1990 Apr;22(2):85-90.

Lähteenmäki P, Rauramo I, Backman T. The levonorgestrel intrauterine system in contraception. Steroids. 2000 Nov;65(10-11):693–7.

Sivin I, el Mahgoub S, McCarthy T, Mishell DR, Shoupe D, Alvarez F, et al. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception. 1990 Oct;42(4):361-78.

Jones RL, Critchley HO. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod. 2000 Aug;15(Suppl 3):162-72.

Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril. 2003 May;79(5):1194-8.

Xu L, Lee BS, Asif S, Kraemer P, Inki P. Satisfaction and health-related quality of life in women with heavy menstrual bleeding; results from a non-interventional trial of the levonorgestrel-releasing intrauterine system or conventional medical therapy. Int J Womens Health. 2014;6:547-54.

Naqaish T, Rizvi F, Khan A, Afzal M. Patient satisfaction for levonorgestrel intrauterine system and norethisterone for treatment of dysfunctional uterine bleeding. J Ayub Med Coll Abbottabad. 2012 Mar;24(1):23-6.

Mercorio F, De Simone R, Di Spiezio Sardo A, Cerrota G, Bifulco G, Vanacore F, et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception. 2003 Apr;67(4):277-80. Gupta B, Mittal S, Misra R, Deka D, Dadhwal V. Levonorgestrel-releasing intrauterine system vs. transcervical endometrial resection for dysfunctional uterine bleeding. Int J Gynaecol Obstet. 2006 Dec;95(3):261-6.

Kriplani A, Awasthi D, Kulshrestha V, Agarwal N. Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma. Int J Gynaecol Obstet. 2012 Jan;116(1):35-8.

Kim JY, No JH, Kim K, Kim YB, Jee BC, Lee JR, et al. Effect of myoma size on failure of thermal balloon ablation or levonorgestrel releasing intrauterine system treatment in women with menorrhagia. Obstet Gynaecol Sci. 2013 Jan;56(1):36-40.

Xie Z-W, Zhang Y-N, Wan S, Xu W-Z, Chen J. Levonorgestrel-releasing intrauterine device is an efficacious contraceptive for women with leiomyoma. J Int Med Res. 2012;40(5):1966-72.

Marret H, Fritel X, Ouldamer L, Bendifallah S, Brun J-L, De Jesus I, et al. Therapeutic management of uterine fibroid tumors: updated French guidelines. Eur J Obstet Gynecol Reprod Biol. 2012 Dec;165(2):156-64.

Downloads

Published

2017-01-04

Issue

Section

Original Research Articles